K. Heller

发表

Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer

L. Bastholt, M. Kreissl, D. Führer, 2016, European Thyroid Journal.

Food Increased the Bioavailability of BMS‐690514, an Orally Active EGFR/HER2/VEGF Receptor Kinase Inhibitor, in Healthy Subjects

G. Derbin, V. Roongta, Jong-Soon Park, 2012, Journal of clinical pharmacology.

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

D. Schadendorf, J. Wolchok, M. Maio, 2010, Cancer immunity.

Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases.

Jeffrey W. Clark, F. Hodi, M. Sznol, 2010 .

Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies.

J. Wolchok, P. Lorigan, S. O’Day, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary follicular lymphoma of the testis: excellent outcome following surgical resection without adjuvant chemotherapy.

J. Teruya-Feldstein, L. Wexler, M. L. La Quaglia, 2004, Journal of pediatric hematology/oncology.

Epstein Barr virus nuclear antigen 1 in healthy virus carriers Distinct memory CD4+ T-cell subsets mediate immune recognition of

H. Zebroski, C. Münz, Beza Seyoum, 2013 .

Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers.

H. Zebroski, C. Münz, Beza Seyoum, 2007, Blood.

Virus-specific CD4+ T cells: ready for direct attack

C. Münz, C. Gurer, K. Heller, 2006, The Journal of experimental medicine.

Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.

M. Sznol, H. Kluger, M. Burke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Children with endemic Burkitt lymphoma are deficient in EBNA1‐specific IFN‐γ T cell responses

R. Ploutz-Snyder, A. Moormann, C. Münz, 2009, International journal of cancer.

Patients with Epstein Barr virus‐positive lymphomas have decreased CD4+ T‐cell responses to the viral nuclear antigen 1

P. Steinherz, C. Münz, A. Chadburn, 2008, International journal of cancer.

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

J. Wolchok, F. Hodi, M. Sznol, 2012, The Lancet. Oncology.

Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans

W. Humphreys, V. Roongta, C. Harbison, 2010, Drug Metabolism and Disposition.

Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning Is Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT

L. Muffly, W. Pang, A. Artz, 2022, Transplantation and Cellular Therapy.

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

I. Weissman, A. Logan, K. Weinberg, 2021, Blood.

EBV-positive lymphoma patients have a selective deficiency in EBV immunity

P. Steinherz, C. Münz, C. Portlock, 2007 .

Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases.

F. Hodi, J. Thompson, A. Pavlick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 4703: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells

L. Swiech, R. Stein, T. Merghoub, 2017 .